Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib.

NCT03140332 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire, Amiens as lead sponsor.

NCT NCT03140332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03140332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib.
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Not applicable
Overall status
Completed
Start date
February 27, 2017
Completion date
February 27, 2020
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, perfusion scanner